DGIdb - MONTELUKAST Drug Record

MONTELUKAST chembl:CHEMBL787 Approved

Alternate Names:

MK-476
SINGULAIR
MONTELUKAST
SINGULAIR®
MONTELUKASTUM
(R-(E))-1-(((1-(3-(2-(7-CHLORO-2-QUINOLINYL)ETHENYL)PHENYL)-3-(2-(1-HYDROXY-1-METHYLETHYL)PHENYL)PROPYL)THIO)METHYL)CYCLOPROPANEACETIC ACID
1-[[[(1 R)-1-[3-[(1E)-2-(7-CHLORO-2-QUINOLINYL)ETHENYL] PHENYL]-3-[2-(1-HYDROXY-1-METHYLETHYL)PHENYL]PROPYL]SULFANYL]METHYL]CYCLOPROPANEACETIC ACID
MONTÉLUKAST
chemidplus:158966-92-8
chembl:CHEMBL787
pubchem.compound:5281040
drugbank:00471
rxcui:88249

Drug Info:

Year of Approval	1998
Drug Class	anti-asthmatic agents
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antiasthmatic agent

(2 More Sources)

Publications:

Nayak, 2004, A review of montelukast in the treatment of asthma and allergic rhinitis., Expert Opin Pharmacother
Alfieri et al., 2007, Heterogeneous effect of leucotriene CysLT1 receptor antagonists on antigen-induced motor and inflammatory responses in guinea-pig airways., Auton Autacoid Pharmacol
Langlois et al., 2006, Montelukast regulates eosinophil protease activity through a leukotriene-independent mechanism., J. Allergy Clin. Immunol.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Hamacher et al., 2007, Montelukast exerts no acute direct effect on NO synthases., Pulm Pharmacol Ther
Zhang et al., 2004, Montelukast modulates lung CysLT(1) receptor expression and eosinophilic inflammation in asthmatic mice., Acta Pharmacol. Sin.
Ramires et al., 2004, Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast., Biochem. Biophys. Res. Commun.
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
Perin P et al., 2014, Polymorphisms in recent GWA identified asthma genes CA10, SGK493, and CTNNA3 are associated with disease severity and treatment response in childhood asthma., Immunogenetics
Hirvensalo P et al., 2018, Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics., Clin Pharmacol Ther
Kim KA et al., 2013, Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans., J Clin Pharmacol
Mougey EB et al., 2009, Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response., Pharmacogenet Genomics
Dahlin A et al., 2015, Genome-Wide Association Study Identifies Novel Pharmacogenomic Loci For Therapeutic Response to Montelukast in Asthma., PLoS One

MONTELUKAST GALNT17

Interaction Score: 6.87

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26083242

Sources:
PharmGKB
MONTELUKAST CA10

Interaction Score: 6.87

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24407380

Sources:
PharmGKB
MONTELUKAST MLLT3

Interaction Score: 3.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26083242

Sources:
PharmGKB
MONTELUKAST CYSLTR1

Interaction Score: 3.43

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name loratadine + montelukast sodium,Claritin + Singulair

Novel drug target Established target

Trial Name montelukast sodium,Singulair

PMIDs:
15013935 17199874 16815146 11752352 16815057 15456537

Sources:
TdgClinicalTrial TEND PharmGKB TTD
MONTELUKAST LTC4S

Interaction Score: 1.72

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
MONTELUKAST ABCC9

Interaction Score: 0.76

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28940478

Sources:
PharmGKB
MONTELUKAST SLCO2B1

Interaction Score: 0.57

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23970434 19151602

Sources:
PharmGKB
MONTELUKAST UGT1A3

Interaction Score: 0.49

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28940478

Sources:
PharmGKB
MONTELUKAST LTA4H

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
MONTELUKAST CYP2C8

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28940478

Sources:
PharmGKB
MONTELUKAST ALOX5

Interaction Score: 0.27

Interaction Types & Directionality:

other/unknown

Interaction Info:

PMIDs:
15474500

Sources:
PharmGKB
MONTELUKAST ABCC1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
MONTELUKAST CYP3A5

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
MONTELUKAST CYP2C9

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
MONTELUKAST CYP2C19

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
MONTELUKAST CYP1A2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
MONTELUKAST CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
MONTELUKAST CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC

TEND: MONTELUKAST
- Version: 01-August-2011
Alternate Names:

MONTELUKAST Primary Drug Name

Drug Info:

Drug Class anti-asthmatic agents

Year of Approval 1998

Publications:
TdgClinicalTrial: MONTELUKAST
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antiasthmatic agent

Drug Class Small Molecule

FDA Approval approved

Publications:
DTC: MONTELUKAST
- Version: 02-September-2020
Alternate Names:

CHEMBL787 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

PharmGKB: montelukast

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem

Hirvensalo P et al., 2018, Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics., Clin Pharmacol Ther

Mougey EB et al., 2009, Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response., Pharmacogenet Genomics

TTD: Montelukast
- Version: 2020.06.01
Alternate Names:

D00QET TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL787
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	loratadine + montelukast sodium,Claritin + Singulair
Novel drug target	Established target
Trial Name	montelukast sodium,Singulair

MONTELUKAST Drug Record

MONTELUKAST chembl:CHEMBL787 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26083242

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24407380

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26083242

Sources: PharmGKB

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name loratadine + montelukast sodium,Claritin + Singulair Novel drug target Established target Trial Name montelukast sodium,Singulair

PMIDs: 15013935 17199874 16815146 11752352 16815057 15456537

Sources: TdgClinicalTrial TEND PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28940478

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23970434 19151602

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28940478

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28940478

Sources: PharmGKB

Interaction Types & Directionality: other/unknown

Interaction Info:

PMIDs: 15474500

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18695978

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

TEND: MONTELUKAST

Alternate Names: MONTELUKAST Primary Drug Name

Drug Info: Drug Class anti-asthmatic agents Year of Approval 1998

Interaction Types & Directionality:

n/a

PMIDs:
26083242

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24407380

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26083242

Sources:
PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name loratadine + montelukast sodium,Claritin + Singulair

Novel drug target Established target

Trial Name montelukast sodium,Singulair

PMIDs:
15013935 17199874 16815146 11752352 16815057 15456537

Sources:
TdgClinicalTrial TEND PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28940478

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23970434 19151602

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28940478

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28940478

Sources:
PharmGKB

Interaction Types & Directionality:

other/unknown

PMIDs:
15474500

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Alternate Names:

MONTELUKAST Primary Drug Name

Drug Info:

Drug Class anti-asthmatic agents

Year of Approval 1998

Drug Info:

Drug Indications antiasthmatic agent

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

CHEMBL787 ChEMBL Drug ID

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Alternate Names:

D00QET TTD Drug ID